P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome
P-2:铂类化疗和放疗结果的风险预测
基本信息
- 批准号:8731333
- 负责人:
- 金额:$ 10.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-12 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdoptedAlcoholsAlgorithmsApoptosisApoptoticBase Excision RepairsBiological AssayBiological MarkersBlood specimenBody Weight decreasedCancer PatientCell Cycle CheckpointCell Cycle RegulationCellsCharacteristicsChestCisplatinClassificationClinicalClinical DataCodeCombined Modality TherapyDNADNA RepairDataDevelopmentDoseDouble Strand Break RepairEnrollmentEnvironmentEpidemiologic StudiesEpidemiologyFamily Cancer HistoryFrequenciesFunctional disorderGenesGeneticGenetic MarkersGenetic PolymorphismGenetic VariationGenotypeGoalsHaplotypesIndividualInflammationIntegration Host FactorsInterviewMachine LearningMalignant neoplasm of lungMeasuresMedicalMedical HistoryMetabolismModalityModelingMolecularMolecular EpidemiologyNon-Small-Cell Lung CarcinomaNormal tissue morphologyNucleic Acid Regulatory SequencesNucleotide Excision RepairOutcomeOxidative StressP-2ParticipantPathway interactionsPatientsPenetrancePerformance StatusPharmaceutical PreparationsPlatinumPlatinum CompoundsPlatinum adductPredispositionProteinsProtocols documentationRNA SplicingRadiationRadiation Induced DNA DamageRadiation ToxicityRadiation therapyRecording of previous eventsResearch InfrastructureRiskRisk AssessmentSeriesSiteSmokingSpecimenStagingSubgroupTexasTherapeuticToxic effectTreatment EfficacyTreatment outcomeTreesTumor TissueUniversitiesVariantanalogbasechemoradiationchemotherapyclinical efficacyclinically relevantcohortdesigndrug metabolismepidemiologic dataexperiencefollow-upgene environment interactionhigh riskimprovednovelprotein functionrepairedresponsetelomeretissue repairtooltumoruptake
项目摘要
The overarching goal of this project is to determine host epidemiologic and genetic factors that will be
predictive of efficacy and toxicity of platinum-based chemotherapy or combined with thoracic radiotherapy in
NSCLC patients. We will construct a well-characterized cohort of 1,200 NSCLC patients (Stages III and IV -
receiving first-line platinum-based chemotherapy ¿ definitive thoracic radiotherapy). This cohort will then be
studied for epidemiologic, clinical and a large number of rationally selected germline polymorphisms to
correlate with the clinical outcome to allow us to construct predictive risk models for clinical efficacy and
toxicity. We estimate there will be ~ 600 patients treated by platinum-based chemotherapy alone, and 600
Stage III patients receiving platinum-based chemotherapy plus definitive thoracic radiotherapy. There are
three specific aims: 1) we will identify novel genetic loci that predict efficacy and toxicity to platinum-based
chemotherapy and radiotherapy in all 1,200 patients. We will adopt a pathway-based genotyping and
analyzing approach to evaluate frequencies .of about 8,000 SNPs in genes involved in pathways relevant to
platinum and radiation response. We will examine individual SNP main effects, haplotypes, and the
cumulative effect of SNPs in modulating efficacy and toxicity. Our hypothesis is that specific genotypes
that alter the metabolism or action of platinum agents or relevant to the genotoxic effects of
radiotherapy may impact the efficacy and toxicity of patients to these therapies. 2) we will apply
machine-learning tools to identify gene-gene and gene-environment interactions influencing NSCLC
outcome. We will develop algorithms to identify subgroups with differing platinum or radiotherapy treatment
efficacy or toxicity. Our hypothesis is that therapeutic response is modulated by common, low
penetrance polymorphisms, and that these polymorphisms interact with each other and/or host
factors in determining response to therapy. 3) we will construct predictive risk models for survival and
toxicity by integrating clinical and epidemiologic data with the genetic data from this project,and additional
information from other R01 studies devoted to these cohorts such as a series of phenotypic assays. We
hypothesize that the addition of genetic markers to the standard clinical and epidemiologic variables
will improve the prediction of survival and toxicity of the final risk assessment models. We will
compare the prediction accuracy among all patients, patients receiving chemotherapy alone, and patients
treated by combined modality. The risk models resulting from this project may permit clinicians to identify
patients before the start of therapy who are most and least likely to benefit or to develop toxicity and will
have immense clinical benefit in terms of planning chemotherapy and radiotherapy for individual patients.
该项目的首要目标是确定宿主流行病学和遗传因素
铂为主的化疗或联合胸腔内放疗的疗效和毒性预测
非小细胞肺癌患者。我们将建立一个具有良好特征的1,200名非小细胞肺癌患者队列(III和IV期-
接受以铂为基础的一线化疗(最终的胸部放射治疗)。届时,这批人将成为
对流行病学、临床和大量合理选择的生殖系多态进行研究,以
与临床结果相关联,以使我们能够构建临床疗效和
毒性。我们估计将有大约600名患者仅接受以铂为基础的化疗,其中600人
接受以铂为基础的化疗加明确的胸部放射治疗的III期患者。确实有
三个具体目标:1)我们将识别预测铂类药物疗效和毒性的新的遗传基因座
所有1,200名患者接受化疗和放射治疗。我们将采用基于途径的基因分型和
基因中约8000个SNPs频率的分析方法
铂和辐射反应。我们将研究单个SNP的主效应、单倍型和
SNPs在调节疗效和毒性方面的累积效应。我们的假设是特定的基因类型
改变铂制剂的新陈代谢或作用,或与其遗传毒性效应有关的
放射治疗可能会影响患者对这些疗法的疗效和毒性。2)我们会申请
识别影响非小细胞肺癌的基因-基因和基因-环境相互作用的机器学习工具
结果。我们将开发算法来识别接受不同铂或放射治疗的亚组
效力或毒性。我们的假设是,治疗反应是由常见的、低水平的
外显性多态,以及这些多态相互作用和/或寄主
决定治疗反应的因素。3)我们将构建可预测的生存和风险模型
毒性,通过将临床和流行病学数据与该项目的遗传数据相结合,以及其他
来自致力于这些队列的其他R01研究的信息,例如一系列表型分析。我们
假设将遗传标记添加到标准的临床和流行病学变量
最终将完善预测生存和毒性的风险评估模型。我们会
比较所有患者、单独接受化疗的患者和患者之间的预测准确性
用综合情态疗法治疗。由该项目产生的风险模型可能允许临床医生识别
在治疗开始前,最有可能和最不可能受益或产生毒性的患者
在为个别患者计划化疗和放射治疗方面具有巨大的临床益处。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xifeng Wu其他文献
Xifeng Wu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xifeng Wu', 18)}}的其他基金
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
连接肥胖和肾细胞癌肿瘤发生的分子途径 (PQ1)
- 批准号:
8383276 - 财政年份:2012
- 资助金额:
$ 10.57万 - 项目类别:
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
连接肥胖和肾细胞癌肿瘤发生的分子途径 (PQ1)
- 批准号:
8538909 - 财政年份:2012
- 资助金额:
$ 10.57万 - 项目类别:
Molecular pathways linking obesity and RCC tumorigenesis (PQ1)
连接肥胖和肾细胞癌肿瘤发生的分子途径 (PQ1)
- 批准号:
8686604 - 财政年份:2012
- 资助金额:
$ 10.57万 - 项目类别:
4th Meeting of the International Consortium of Bladder Cancer (ICBC)
国际膀胱癌联盟(ICBC)第四次会议
- 批准号:
8006232 - 财政年份:2010
- 资助金额:
$ 10.57万 - 项目类别:
Lung Cancer Chemoradiation: Predictors of Survival
肺癌放化疗:生存的预测因素
- 批准号:
7939475 - 财政年份:2009
- 资助金额:
$ 10.57万 - 项目类别:
P-2: Risk Prediction of platinum-based chemotherapy and Radiotherapy Outcome
P-2:铂类化疗和放疗结果的风险预测
- 批准号:
7921399 - 财政年份:2009
- 资助金额:
$ 10.57万 - 项目类别:
Genome-Wide Association Analysis of Bladder Cancer
膀胱癌的全基因组关联分析
- 批准号:
7935041 - 财政年份:2009
- 资助金额:
$ 10.57万 - 项目类别:
Genome-Wide Association Analysis of Bladder Cancer
膀胱癌的全基因组关联分析
- 批准号:
8054297 - 财政年份:2008
- 资助金额:
$ 10.57万 - 项目类别:
Markers of Susceptibility as Predictors of Blasser Cancer Recurrence
易感性标记物作为 Blasser 癌症复发的预测因子
- 批准号:
7729505 - 财政年份:2008
- 资助金额:
$ 10.57万 - 项目类别:
Genome-Wide Association Analysis of Bladder Cancer
膀胱癌的全基因组关联分析
- 批准号:
7591153 - 财政年份:2008
- 资助金额:
$ 10.57万 - 项目类别:
相似海外基金
How novices write code: discovering best practices and how they can be adopted
新手如何编写代码:发现最佳实践以及如何采用它们
- 批准号:
2315783 - 财政年份:2023
- 资助金额:
$ 10.57万 - 项目类别:
Standard Grant
One or Several Mothers: The Adopted Child as Critical and Clinical Subject
一位或多位母亲:收养的孩子作为关键和临床对象
- 批准号:
2719534 - 财政年份:2022
- 资助金额:
$ 10.57万 - 项目类别:
Studentship
A material investigation of the ceramic shards excavated from the Omuro Ninsei kiln site: Production techniques adopted by Nonomura Ninsei.
对大室仁清窑遗址出土的陶瓷碎片进行材质调查:野野村仁清采用的生产技术。
- 批准号:
20K01113 - 财政年份:2020
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633211 - 财政年份:2020
- 资助金额:
$ 10.57万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2436895 - 财政年份:2020
- 资助金额:
$ 10.57万 - 项目类别:
Studentship
A comparative study of disabled children and their adopted maternal figures in French and English Romantic Literature
英法浪漫主义文学中残疾儿童及其收养母亲形象的比较研究
- 批准号:
2633207 - 财政年份:2020
- 资助金额:
$ 10.57万 - 项目类别:
Studentship
A Study on Mutual Funds Adopted for Individual Defined Contribution Pension Plans
个人设定缴存养老金计划采用共同基金的研究
- 批准号:
19K01745 - 财政年份:2019
- 资助金额:
$ 10.57万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The limits of development: State structural policy, comparing systems adopted in two European mountain regions (1945-1989)
发展的限制:国家结构政策,比较欧洲两个山区采用的制度(1945-1989)
- 批准号:
426559561 - 财政年份:2019
- 资助金额:
$ 10.57万 - 项目类别:
Research Grants
Securing a Sense of Safety for Adopted Children in Middle Childhood
确保被收养儿童的中期安全感
- 批准号:
2236701 - 财政年份:2019
- 资助金额:
$ 10.57万 - 项目类别:
Studentship
Structural and functional analyses of a bacterial protein translocation domain that has adopted diverse pathogenic effector functions within host cells
对宿主细胞内采用多种致病效应功能的细菌蛋白易位结构域进行结构和功能分析
- 批准号:
415543446 - 财政年份:2019
- 资助金额:
$ 10.57万 - 项目类别:
Research Fellowships